What is OssDsign?
OssDsign is a global developer and provider of next-generation orthobiologics, leveraging advanced material science to accelerate the body's natural healing processes. Their core innovation, OssDsign Catalyst, is a nanosynthetic bone graft engineered for rapid and dependable bone formation, particularly beneficial in interbody fusion surgeries. The company serves healthcare professionals and surgeons seeking cutting-edge, effective solutions in orthopedic procedures, aiming to elevate patient recovery and quality of life through their sophisticated medical product portfolio.
How much funding has OssDsign raised?
OssDsign has raised a total of $10.9M across 1 funding round:
Private Equity
$10.9M
Private Equity (2015): $10.9M with participation from Karolinska Development
Key Investors in OssDsign
Karolinska Development
Karolinska Development is a venture capital firm specializing in life sciences, with a focus on growth capital and early-stage investments in pharmaceutical research, medical technology, and biotechnology, primarily within the Nordic region.
What's next for OssDsign?
The recent major strategic investment signals a pivotal growth phase for OssDsign, likely enabling further research and development into their material science innovations. This capital infusion is expected to bolster their global market penetration and expand the application of their orthobiologic products. OssDsign is poised to solidify its leadership in the orthopedics sector, driving advancements in patient care and surgical outcomes through continued product development and strategic partnerships.
See full OssDsign company page
